CD274 and neoplasm: DDR gene alterations have also been associated with an increased likelihood of response to PD-1/PD-L1 blockade, potentially mediated by increased tumor mutational burden (TMB), raising the hypothesis that such tumors may be particularly sensitive to cisplatin plus PD-1/PD-L1 blockade combination regimens21,22.